EmeraMed: Targeting the cause of diseases.
Oxidative stress releases free radicals and is a major part of all illnesses. Irminix® captures free radicals, which are unstable molecules that can damage the cells in your body. Additionally Irminix® captures the heavy metals mercury and iron which helps create free radicals and thereby helps restore normal function to the mitochondria and overall health.
COPD: A Phase 2a clinical trial has been completed in summer of 2018 and found Irminix® to be safe with no adverse effects.
Mercury poisoning: Orphan Drug Designation has been granted for the prevention and treatment of mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed and found Irminix® to be effective and safe with no adverse effects.
Iron overload: Preclinical studies for iron overload have been completed. Animals specially bred to have great difficulty with iron accumulation in critical organs were fed Irminix®. The animals that ingested Irminix® maintained normal iron levels and suffered no injury. The animals who did not were soon iron toxic.
Other conditions: Preclinical studies are ongoing for several other indications.
Learn about our company, mission and board of directors.
Irminix® has been approved for compassionate use.
Latest News, Research, Clinical Trials, Press and Newsletters.
Investor Information about EmeraMed Ltd.
Discover The Future of Health
We are committed to improving health by way of our unique metal chelator and antioxidant, Irminix®